Navigation Links
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
Date:6/7/2009

ride (8 mg, once daily) in patients with type 2 diabetes. Patients were treated previously with diet/exercise or low doses of one oral antidiabetic drug (OAD). The trial had a 52-week randomized, double-blind period followed by the one-year extension; 59% entered the extension period of the trial and 43% of these patients completed the full two-year study period.

LEAD(TM) 3: two-year data

    Two years                Liraglutide       Liraglutide       Glimepiride
     monotherapy             1.8 mg, QD        1.2 mg, QD        8 mg, QD
                             N=154             N=149             N=137

    Diabetes duration,
     years at baseline         5.0                5.0              5.0

    Previous treatment:
    % diet/exercise             35%                38%              34%
    % OAD monotherapy           65%                62%              66%

    A1C % at baseline          8.1                8.1              8.0

    BMI, kg/m(2) at
     baseline                   33                 33               33

    Change in A1C% from
     baseline                 -1.1               -0.9             -0.6

    Change in A1C%  from
     baseline (in
     patients with <3
     years duration of
     diabetes)                -1.4               -1.1             -0.7

    % A1C <7.0%                 58                 53               37

    Change FPG (Fasting
     Plasma Glucose)
     mg/dL from baseline       -27                -24               -6

    Weight change, kg
     from baseline            -2.7               -2.1              1.1

    Minor hypoglycemic
     events/patient/year      0.23               0.21             1.76

Safety and tolerability of liraglutide

The rate of minor hypoglycemia was statistically significantly lower with both liraglutide dose groups compared to the glimepiride-t
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
2. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
3. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
10. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
11. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... data, competitor focus, and new drug-eluting technologies to drive ... according to Millennium Research Group WALTHAM, Mass., May ... European Markets for Peripheral Vascular (PV) Devices 2009 ... that treat lower extremity peripheral artery disease in Europe ...
... Results and additional analyses from the Phase II portion ... drug relaxin for the treatment of acute heart failure ... annual meeting of the Heart Failure Association of the ... Metra, M.D., professor of cardiology at the University of ...
Cached Medicine Technology:Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 2Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 3Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... leading provider,of employee benefit consulting and insurance brokerage ... announces the expansion of its West Coast,Health Care ... has entered the,Consortium beginning January 1, 2008, joining ... Wilson Sonsini Goodrich & Rosati PC as,participating firms ...
... the hospital might be best course, study finds , , FRIDAY, ... with pneumonia at home is as safe and effective as ... 2 million children under the age of 5 each year. ... researchers report. , "Severe in pneumonia in children can ...
... J. Fox,Foundation has committed up to $3.8 million ... treat Parkinson,s disease by reducing expression,of the protein ... Farrer,PhD, of Mayo Clinic Jacksonville (Florida) with collaborators ... Center will work,to optimize a small interfering RNA ...
... well with more cost-effective conventional film screenings, study says ... from a landmark trial released in 2005 concluded that ... than conventional film mammography was. , But a new ... Internal Medicine , concludes that digital mammography is not ...
... Pa., Jan. 4 Coventry said today that,the ... New York approved an,agreement between the Company and ... for the resolution of outstanding issues related to,life ... declared bankruptcy in June 2007., "I am ...
... patients benefit from educational programs as a supplement ... symptoms, lose weight and increase physical activity, a ... produce different results for this notoriously difficult to ... the University of Michigan suggests that if hospitals ...
Cached Medicine News:Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 2Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 3Health News:Treating Childhood Pneumonia at Home Could Save Lives in Developing Countries 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 3Health News:Not All Women Need Digital Mammograms 2Health News:Coventry and Ritchie Reach Agreement on Protection of Policyowner Information 2Health News:Heart patients find education programs lead to better health 2
... with 24-well x 0.2ml sub-ambient block and ... thermistor) Heating rates: up to 3C/second; Accurate ... Excellent uniformity: better than 0.5C within 15 ... programming: directory program storage of up to ...
... maximizes what a thermal cycler can do ... formats, an easy graphic interface, and best ... PCR. The iCycler thermal cycler will raise ... can do for you.,, iCycler Thermal Cycler ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... RoboCycler Gradient 40 or 96 temperature cyclers, the ... linear temperature range of up to 14 or ... with a temperature difference of up to 2C ... you can test up to 12 different annealing ...
Medicine Products: